Entera Bio Ltd.
ENTX
$2.17
-$0.12-5.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.75% | 50.19% | -4.14% | 2.55% | -55.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | 44.44% |
| Total Operating Expenses | 23.23% | 28.37% | -4.64% | -6.78% | -44.53% |
| Operating Income | -19.05% | -26.61% | 7.08% | 6.78% | 44.31% |
| Income Before Tax | -17.49% | -28.55% | 7.74% | 7.90% | 35.25% |
| Income Tax Expenses | -- | -- | -- | -- | 100.00% |
| Earnings from Continuing Operations | -18.20% | -26.99% | 7.74% | 7.90% | 34.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.20% | -26.99% | 7.74% | 7.90% | 34.27% |
| EBIT | -19.05% | -26.61% | 7.08% | 6.78% | 44.31% |
| EBITDA | -19.28% | -26.90% | 6.95% | 6.78% | 44.43% |
| EPS Basic | 10.53% | 2.78% | 28.38% | 27.76% | 35.99% |
| Normalized Basic EPS | 10.93% | 1.57% | 28.37% | 27.79% | 45.18% |
| EPS Diluted | 10.53% | 2.78% | 28.38% | 27.76% | 35.99% |
| Normalized Diluted EPS | 10.93% | 1.57% | 28.37% | 27.79% | 45.18% |
| Average Basic Shares Outstanding | 32.15% | 30.65% | 28.73% | 27.51% | 2.72% |
| Average Diluted Shares Outstanding | 32.15% | 30.65% | 28.73% | 27.51% | 2.72% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |